Pharma Focus America
ThermoFisher Scientific - Go beyond the catalog

Bayer Invests $250 Million in First Global Cell Therapy Manufacturing Facility for Regenerative Medicines


The facility aims to produce cell and gene therapies on a global scale, making them more accessible worldwide.


It prepares for potential commercial launches, including BlueRock Therapeutics' investigational cell therapy for Parkinson's disease, Bemdaneprocel (BRT-DA01).

The facility addresses industry-wide manufacturing capacity bottlenecks for regenerative medicines.

It's a 100,000 sq. ft. building and is Bayer's first fully electric pharmaceutical manufacturing plant, aligning with sustainability goals.

The facility offers flexible, modular space for cell culture, viral transduction, and automated filling of cell therapies.

Leverages expertise in iPSC and CAR-T characterization, process development, analytics, and clinical to commercial production.

This facility is part of Bayer's larger investments in its biologic pipeline, covering protein therapeutics, cell, and gene therapies.


Name: Bayer

Type: Expansion

Sartorius Lab Balance CleaningFestival of Biologics San Diego 2024Equinix accelerated medical research...World Vaccine Congress Europe 2024World Orphan Drug Congress 2024World Vaccine Congress Washington 2024Future Labs Live USA 2024Interphex 2024Pharma USA 2024Healthcare CNO SummitHealthcare CMO Summit